Envoy Medical Completes Enrollment for Pivotal Trial of Fully Implanted Cochlear Implant

Envoy Medical, Inc. (NASDAQ: COCH) has completed patient enrollment in its pivotal clinical trial evaluating the investigational Acclaim fully implanted cochlear implant. This milestone moves the company closer to potential regulatory approval for the device, which targets adults with severe to profound sensorineural hearing loss.

The company believes the technology could significantly improve the cochlear implant experience by eliminating the need for external hardware.

Pivotal clinical trial reaches full enrollment

The U.S. pivotal study enrolled 56 patients who received the Acclaim cochlear implant, allowing Envoy Medical to reach its targeted enrollment. Researchers designed the trial to evaluate the safety and effectiveness of the device in adults with severe hearing loss.

Envoy Medical plans to use the clinical data to support a Premarket Approval submission to the U.S. Food and Drug Administration. The company currently expects to submit its FDA application in the second quarter of 2027.

First fully implanted cochlear implant system

The Acclaim cochlear implant aims to become the first fully implanted cochlear implant system of its kind. Unlike traditional cochlear implants, which rely on external microphones and processors worn behind the ear, the Acclaim device operates entirely beneath the skin.

Envoy Medical developed the system with an implanted piezoelectric sensor that captures sound using the ear’s natural structures. By removing external components, the device may provide a more natural hearing experience while improving convenience and usability for patients.

Breakthrough device designation from the FDA

The U.S. Food and Drug Administration previously granted Breakthrough Device Designation to the Acclaim cochlear implant. The FDA awards this designation to medical technologies that may offer meaningful improvements over existing treatments and that could benefit from accelerated development and regulatory review.

The Acclaim device remains investigational and is currently available only within clinical trials until regulators approve it.

Investor perspective

For investors, the completion of patient enrollment marks an important development milestone for Envoy Medical. Progress at this stage of clinical evaluation brings the company closer to potential FDA approval and future commercialization.

If approved, the Acclaim cochlear implant could address a large global market for hearing restoration while offering a differentiated alternative to conventional cochlear implant systems.

Bottom line

Envoy Medical’s completion of enrollment in the pivotal Acclaim cochlear implant trial represents a key step toward regulatory approval. With clinical data expected to support a future FDA submission, the company continues to advance a fully implanted hearing technology that could reshape the cochlear implant market.